Subscribe

Kim Slocum, KDS Consulting, LLC

Articles by Kim Slocum, KDS Consulting, LLC

The downside of pricing specialty pharmaceuticals too high

ByKim Slocum, KDS Consulting, LLC

May 1st 2013

Latest Updated Articles

The downside of pricing specialty pharmaceuticals too high
Published: May 1st 2013 | Updated:

Trending on Pharmaceutical Commerce

TrumpRx Launches With MFN-Based Drug Discounts

FTC–Express Scripts Settlement Targets PBM Rebates, Transparency, and Patient Drug Costs

The Great Repricing: Commercial Channel Under Pressure

Pharma's Year of Two Halves

Your Copay Program Is Protecting Access. Is It Also Protecting Gross-to-Net?